Diamedica Therapeutics Inc. · NASDAQ:DMAC
Diamedica Therapeutics — Q4 2025 Earnings Presentation
40 slides from Diamedica Therapeutics's earnings presentation, Mar 31, 2026
Slide 1: Corporate Presentation
Corporate Presentation March 2026 Transforming Care for Preeclampsia and Stroke
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expe
Slide 3: DM199 has Potential to be First Approved Treatment Option
DM199 has Potential to be First Approved treatment Option Recombinant human KLK1 protein for vascular and ischemic diseases Preeclampsia (PE) and Fetal Growth Restriction (FGR): Ongoing phase 2 trial 〉Increase blood flow to placenta and reduce blood pressure and endothelial dysfunction in $5B+ U.S.
Slide 4: DiaMedica Pipeline
DiaMedica Pipeline FPI: First patient in * Investigator sponsored trial © 2026 DiaMedica Therapeutics. All Rights Reserved. 4 **As of 11/13/25 conference call
Slide 5: Preeclampsia & Fetal Growth Restriction
Preeclampsia & Fetal Growth Restriction
Slide 6: Early-Onset Preeclampsia & FGR: Severe Conditions with $5B+ U.S. Opportunity
Early-Onset Preeclampsia & FGR: Severe Conditions with $5B+ U.S. Opportunity Refractory hypertension drives ~50% of deliveries1 Disease Overview Annual Incidence 〉Preeclampsia (PE): A life-threatening high blood pressure disorder accompanied by multi-system PE Globally2 ~10,000,000 organ damage that
Slide 7: Preeclampsia Early Delivery Has Poorer Outcomes and Higher Costs
Preeclampsia Early Delivery Has Poorer Outcomes and Higher Costs Prolonging pregnancy can reduce neonate morbidity and mortality and associated costs Preterm Neonatal Major Morbidity* and Mortality by Gestational Age 60% 50% Percentage of neonates (%) Death Major morbidity 40% 30% 20% 10% 0% 23 24 2
Slide 8: Stage 1 of Preeclampsia: Placental Disease
Stage 1 of Preeclampsia: Placental Disease Inadequate spiral artery development in the first trimester leads to reduced blood flow and hypoxia Normal Pregnancy Preeclampsia → Widened Spiral Arteries (5- to 10-fold)1 → Narrow Spiral Arteries → Healthy Blood Flow → Low Blood Flow Maternal Spiral Arter
Slide 9: Stage of Preeclampsia: Endothelial Dysfunction & Maternal Disease
Stage 2 of Preeclampsia: Endothelial Dysfunction & Maternal Disease Noxious factors released from the ischemic placenta cause endothelial dysfunction Endothelial Nitric Oxide Prostacyclin EDHFs VEGF Dysfunction Systemic Pathology Depressed Pathways BRAIN Oxidative stress (In Endothelial Cells) • Ecl
Slide 10: Preeclampsia: Limited and Insufficient Treatments: Major Unmet Medical Need
Preeclampsia: Limited and Insufficient Treatments: Major Unmet Medical Need 〉No disease modifying agents for preeclampsia 〉First-line antihypertensives, ACE inhibitors and ARBs, are CONTRAINDICATED in pregnancy Medication Drugs Comments Alpha/Beta blocker (Labetalol) 〉Reduce blood pressure and mater
Slide 11: DM199 MOA
DM199 MOA NZ re DiaMedica AWS THERAPEUTICS
Slide 12: KLK1 Levels Lower in Preeclampsia Pregnancies
KLK1 Levels Lower in Preeclampsia Pregnancies Significant relationship between KLK1 levels, Preeclampsia and Preeclampsia with severe features KLK1 Levels (N=96) KLK1 (ng/mL) Serum Levels 1. Yuan etc. Plasma concentrations of tissue kallikrein in normal and preeclamptic pregnancies. Hypertension in
Slide 13: DM199 (rhKLK1 – rinvecalinase alfa) Novel Mechanism of Action
DM199 (rhKLK1 – rinvecalinase alfa) Novel Mechanism of Action DM199 produces all three major endothelial derived vasodilating factors Nitric Oxide - cGMP DM199 (rhKLK1) Kininogen Bradykinin BK2R Prostacyclin - cAMP EDHFs 〉 KLK1 is made predominately in kidneys (present also in the vasculature and br
Slide 14: Relative Contribution of Major Endothelial Derived Vasodilating Factors
Relative Contribution of 3 Major Endothelial Derived Vasodilating Factors1 EDHF is critical in microvasculature and compensates when NO and PGI2 signaling are compromised Conduit Arteries Terminal Branches Arterioles 〉 Arterioles are the primary site of resistance in the vascular tree and the most s
Slide 15: DM199: The Ideal Drug Profile to Treat Preeclampsia
DM199: The Ideal Drug Profile to Treat Preeclampsia Potential Disease Modifying Mechanism of Action DM199 Nitric Oxide Prostacyclin EDHFs VEGF DM199 Profile Increase Placental Perfusion Repair Endothelium & Reduce Blood Pressure Pro-inflammatory 01 Oxidative cytokines 02 Endothelial Repair, DM199 ta
Slide 16: Interim Phase 2 (Part 1a) Results
Interim Phase 2 (Part 1a) Results
Slide 17: DM199 Preeclampsia Phase 2 IST Trial: Part 1a
Part 1 Overview DM199 Preeclampsia Phase 2 IST Trial: Part 1a 〉 27-42 weeks gestation (singleton) Women planned for delivery within 72 hours 〉 >150 systolic blood pressure 〉 Receiving standard of care Part 1A - Dose Escalation (3x3 Design) 〉 <72 hours scheduled for delivery C10 2.5ug/kg IV + 15.0ug/
Slide 18: DM199 Generally Safe and Well Tolerated
DM199 Generally Safe and Well Tolerated 〉No serious TEAEs reported 〉Observed adverse events comparable to those typically seen in this patient population Maternal Treatment-Emergent Adverse Events TEAE N=28 [n(%)] Dose Cohorts Nausea 4 (14%) C8 (n=2), C9 (n=2) Headache 3 (11%) C3 (n=1), C6 (n=2) Flu
Slide 19: DM199 Not Detected in Umbilical Cord Blood in Any Dose Cohort
DM199 Not Detected (ND) in Umbilical Cord Blood in Any Dose Cohort 〉At delivery, DM199 not detected in any cord blood samples, while DM199 dose-dependent increase in maternal plasma 〉Suggests DM199 does not cross the placental barrier, an important safety profile Average Plasma DM199 Concentrations
Slide 20: Reduced Blood Pressure at Prespecified 5-Minute Post-Infusion Endpoint
DM199 Reduced Blood Pressure at Prespecified 5-Minute Post-Infusion Endpoint Pooled Cohorts C6–C9 significant reductions in SBP (-25 mmHg, p=0.0003) and DBP (-13 mmHg, p=0.0007) Systolic Diastolic Cohorts 6 – 9 10 Cohorts 6 – 9 5 Dose Range For Further Clinical Investigation Dose Range For Further C
Slide 21: Significantly Reduced Systolic & Diastolic Blood Pressure
DM199 Significantly Reduced Systolic & Diastolic Blood Pressure Pooled analysis of Cohorts 6-9 (IV: 1-2 μg/kg and SC: 6-12 μg/kg), n=122 Systolic Blood Pressure Diastolic Blood Pressure 175 110 170 105 165 167 104 Severe hypertension (AJOG) Average1 SBP (mmHg) Average1 DBP (mmHg) 160 -15 100 -10 -14
Slide 22: Significantly Reduced Uterine Artery Resistance
DM199 Significantly Reduced Uterine Artery Resistance Suggests Enhanced Blood Flow to Placenta Placental Perfusion 2.5 2 2 Uterine Artery Pulsatility Index Reduced blood flow resistance Cohorts 1&2 〉Doppler ultrasound measured uterine artery dilation 1.5 Cohort 3 at baseline and 2 hours post IV infu
Slide 23: DM199: The Ideal Drug Profile to Treat Preeclampsia
DM199: The Ideal Drug Profile to Treat Preeclampsia Potential Disease Modifying Mechanism of Action DM199 Nitric Oxide Prostacyclin EDHFs VEGF DM199 Profile Cascade DM199 Placental High Blood Endothelial Hypoxia Pressure Dysfunction 〉 Improves placental 〉 Lowers blood pressure 〉 Restores endothelial
Slide 24: DM199 Emerging Data Support Path to Approval for Preeclampsia
DM199 Emerging Data Support Path to Approval for Preeclampsia DM199 Phase 2 IST: 120+ Patients 〉 Delivery within 72 hours (n=72) 〉 Part 1a (n=31) 〉 Early onset Preeclampsia (n=30) 〉 Fetal Growth Restriction (n=30) DM199 Phase 2: 30+ Patients 〉 Early onset Preeclampsia DM199 Phase 3 〉 Early onset Pre
Slide 25: Acute Ischemic Stroke
Phase 2/3 Trial: Enrolling Acute Ischemic Stroke
Slide 26: Acute Ischemic Stroke: High Unmet Need with $10B+ U.S. Opportunity
Acute Ischemic Stroke: High Unmet Need with $10B+ U.S. Opportunity 〉7M+ acute ischemic strokes occur globally each year5 and ~700k within the U.S.1-3 〉Only ~20% patients receive either tPA and/or Mechanical Thrombectomy - 1st line therapies3,4 500K+ patients in U.S. with no treatment option HOURS St
Slide 27: Ischemia Naturally Induces Upregulation of Bradykinin Receptors
Ischemia Naturally Induces Upregulation of Bradykinin 2 Receptors (BK2R) DM199 has potential to enhance BK2R activation & promote focal vasodilation in the penumbra Brain Artery Under Different Conditions 1 2 3 Normal Conditions Ischemic Conditions Ischemic Conditions + DM199 ENDOTHELIAL CELL ENDOTH
Slide 28: DM199: May Improve Collateral Circulation in Acute Ischemic Stroke
DM199: May Improve Collateral Circulation in Acute Ischemic Stroke Novel mechanism with potential to improve stroke outcomes & reduce risk of stroke recurrence Early stroke No DM199 treatment DM199 treatment DM199 does not need to pass the blood-brain barrier to deliver therapeutic benefit. DM199 fa
Slide 29: Human Urinary KLK1 (HUK): Safe and Efficacious Treatment for AIS
Human Urinary KLK1 (HUK): Safe and Efficacious Treatment for AIS Guided DM199 development, informing optimal dosing, target patients, & treatment protocols 〉HUK for AIS: – Marketed by Shanghai Pharmaceuticals under Kailikang® – Ameliorates neurological symptoms with few adverse events1 〉Up to 1 mill
Slide 30: AIS Phase 2 Results: Improved Excellent Outcomes in Non-MT Subgroup
DM199 AIS Phase 2 Results: Improved Excellent Outcomes in Non-MT Subgroup Patient population closely aligns with ReMEDy2 Phase 2/3 trial mRS ≤ 1 at 90 Days (Non-MT Participants) Target Population % of Participants at Day 90 (excluding severe) +19% +15% Placebo DM199 Placebo DM199 N=21 N=24 N=15 N=19
Slide 31: AIS Phase 2 Results: Comparison with tPA Data
DM199 AIS Phase 2 Results: Comparison with tPA Data Clinically relevant outcomes with DM199 offering treatment window to 24 hours Comparison of Absolute Improvements in mRS ≤ 1 vs Placebo (DM199 Phase 2 and tPA analysis; excludes MT treated participants) 20 % of Participants at Day 90 vs Placebo 19%
Slide 32: AIS Phase 2/3 Pivotal Trial
DM199 AIS Phase 2/3 Pivotal Trial Overview Endpoints at Day 90 DM199 (rhKLK1) 〉 Moderate AIS: NIHSS: 5-15 Primary: 〉 Adaptive Design Modified Rankin Score (mRS) ≤1 R 1:1 randomization – Interim analysis @ N=200 Secondary: – Intended to enroll N=~300 Placebo mRS shift, mortality, NIHSS, BI and 〉 Up t
Slide 33: Corporate Summary
Corporate Summary lb. svZ DiaMedica fi\S A
Slide 34: Multi-layered IP and Exclusivity Position
DM199 Multi-layered IP and Exclusivity Position 〉Key manufacturing challenges solved: protein activity, stability and economical scale Protein Development Patents and Exclusively Regulatory & Trade Secrets Licensed Technology Exclusivity DM199 (rhKLK1): Excellent Enzymatic Patents1 U.S.: Anticipate
Slide 35: Leadership
Leadership Board of Directors James Parsons, Chairman of the Board 20+ years as a life sciences CFO for several companies. Former CFO Trillium Therapeutics (Acquired by Pfizer for ~$2.2B). Rick Pauls, President & Chief Executive Officer Michael Giuffre, MD Clinical Professor of Cardiac Sciences and
Slide 36: Company Overview
Lead Program: DM199 - Novel, Late-Stage Biologic Therapy Company 〉 Recombinant KLK1 (rhKLK1) protein with FDA Fast-Track Designation 〉 IP until '39 (+ potential 5-year ext.) & expected 12 years regulatory exclusivity Overview 〉 >300 patients dosed with DM199 across multiple studies Cash: $67 million
Slide 37: Thank You!
Thank You! Nasdaq: dmac www.diamedica.com
Slide 38: Appendix
APPENDIX + DiaMedica “| WH ZI
Slide 39: Phase 2 CKD Trial Significantly Lowered Systolic Blood Pressure Over 95 Days
DM199 Phase 2 CKD Trial Significantly Lowered Systolic Blood Pressure Over 95 Days Systolic Blood Pressure (SBP) was only reduced in cohorts with baseline >130 mmHg 〉 Demonstrating sustained blood pressure control 〉 Participants received SC dosing and were on optimized blood pressure medications Sub
Slide 40: Clinical Summary: >300 patients dosed with DM199 to date
Clinical Summary: >300 patients dosed with DM199 to date Phase I/IIa Healthy Volunteers & Type 2 Diabetes Mellitus Part A - Healthy Volunteers (n=30) Part B - Type 2 Diabetes Mellitus (n= 7) Part C - Healthy Volunteers (n=12) Part D - Type 2 Diabetes Mellitus (n= 25) 〉Generally safe and well tolerat
DiaMedica Therapeutics — Q4 2025 Earnings Presentation on 6ix